Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8740922 | Journal of Microbiology, Immunology and Infection | 2018 | 6 Pages |
Abstract
We observed almost no resistance to the tested second-line antituberculosis drugs among non-MDR-Mtbs. Anti-tuberculosis regimen with pyrazinamide, ethambutol, fluoroquinolone, kanamycin, cycloserine and p-aminosalicylic acid can be empirically used for newly diagnosed MDR-TB cases. For previously treated MDR-TB patients, empirical ethambutol, pyrazinamide, ofloxacin, or moxifloxacin may not provide effective treatment because the resistance rates to these drugs were all >50%.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Cheng-Yu Kuo, Wen-Hung Wang, Chung-Hao Huang, Yen-Hsu Chen, Po-Liang Lu,